Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048542 · ClinicalTrials.gov registry record · Phase 3
Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 171
- Enrollment target
NCT00048542 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 171 participants.
The verdict
NCT00048542, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 171 participants
- Enrollment target
Study Summary
This is a multicenter, Phase 3 randomized, placebo-controlled study designed to evaluate adalimumab in children 4 to 17 years old with polyarticular juvenile idiopathic arthritis (JIA) who are either methotrexate (MTX) treated or non-MTX treated.
Interventions
- BIOLOGICAL Double-Blind Adalimumab/Placebo + MTX
- BIOLOGICAL Double-Blind Adalimumab/Placebo
- DRUG OLE BSA Adalimumab +/- MTX
- DRUG OLE FD Adalimumab +/- MTX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2002-09 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048542
The ClinicalTrials.gov registry entry for NCT00048542 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Double-Blind Adalimumab/Placebo + MTX is the first listed.
NCT00048542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00048542 about?
NCT00048542 is a clinical study titled "Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)". This is a multicenter, Phase 3 randomized, placebo-controlled study designed to evaluate adalimumab in children 4 to 17 years old with polyarticular juvenile idiopathic arthritis (JIA) who are either methotrexate (MTX) treated or non-MTX treated.
What is the current status of trial NCT00048542?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 171 participants. The study started on 2002-09. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00048542?
The interventions under investigation include: Double-Blind Adalimumab/Placebo + MTX (BIOLOGICAL), Double-Blind Adalimumab/Placebo (BIOLOGICAL), OLE BSA Adalimumab +/- MTX (DRUG), OLE FD Adalimumab +/- MTX (DRUG).
Who is sponsoring clinical trial NCT00048542?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.